Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint was overall response rate (ORR) and the ORR achieved for the study was 40%.
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
RTKC-0511-014
NCT00054886
January 2003
August 2004
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Las Vegas, Nevada 89128 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |